Basosquamous Carcinoma: A Single Centre Clinicopathological Evaluation and Proposal of an Evidence-Based Protocol.

J Skin Cancer · 2018 · PMC6008864 · PMID 29973992

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

An initial randomised controlled trial studying the use of MMS for facial basal cell carcinoma in 408 patients with 30 months of follow-up demonstrated that the use of MMS slightly lowered the recurrence rates of BCCs, but this decrease did not reach statistical significance [ 33 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.